lifestyle.careersavvy.co.uk

Author: Medicus Pharma Ltd

Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset

March 9, 2026
Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort

March 5, 2026
Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort

March 5, 2026
Medicus Pharma To Participate in the 38th Annual Roth Conference

March 3, 2026
Medicus Pharma on Bloomberg World

February 18, 2026
Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk

February 16, 2026
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony

February 2, 2026
Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile

January 28, 2026
Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026

January 22, 2026
Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform

January 5, 2026